<DOC>
	<DOCNO>NCT01247402</DOCNO>
	<brief_summary>Prospective monocenter single-blind randomize ( 1:1 ) investigator sponsor clinical trial , consecutive patient candidate percutaneous intervention angioplasty treat symptomatic in-stent restenosis SFA P1 segment popliteal artery assign one two study arm : 1 . Treatment Arm : Paclitaxel elute percutaneous transluminal angioplasty ( PePTA ) 2 . Control Arm : standard percutaneous transluminal angioplasty ( sPTA ) . Purpose : To evaluate morphologic clinical efficacy Paclitaxel elute percutaneous transluminal angioplasty ( PePTA ) reduction restenosis SFA PA stent compare standard percutaneous transluminal angioplasty ( sPTA ) .</brief_summary>
	<brief_title>Paclitaxel Balloon Versus Standard Balloon In-stent Restenoses Superficial Femoral Artery ( PACUBA I Trial )</brief_title>
	<detailed_description>Introduction Restenosis endovascular stenting nitinol stent occur 30 % patient 12 month 50 % 24 month . The rate recurrence repeat treatment SFA in-stent restenoses range 70 % 6 month . A recent clinical trial suggest significant inhibition re-restenosis treatment restenosis coronary stent Paclitaxel-coated angioplasty balloon . Study Design Prospective monocenter single-blind randomize ( 1:1 ) investigator sponsor clinical trial , consecutive patient candidate percutaneous intervention angioplasty treat symptomatic in-stent restenosis SFA P1 segment popliteal artery assign one two study arm : 1 . Treatment Arm : Paclitaxel elute percutaneous transluminal angioplasty ( PePTA ) 2 . Control Arm : standard percutaneous transluminal angioplasty ( sPTA ) . Subject Population : Consecutive subject symptomatic in-stent restenosis SFA P1 segment popliteal artery screen enrol base study inclusion exclusion criterion . Objectives : To evaluate morphologic clinical efficacy Paclitaxel elute percutaneous transluminal angioplasty ( PePTA ) reduction restenosis SFA PA stent compare standard percutaneous transluminal angioplasty ( sPTA ) . Primary Endpoints : Primary patency 6 month follow , define &lt; 50 % * diameter stenosis demonstrate CDUS CTA absence clinically drive TLR ( Target Lesion Revascularization ) follow-up . Clinically driven TLR define reintervention target lesion due presence symptomatic &gt; 50 % * diameter stenosis . Secondary Endpoints : 1 . Technical Success : achievement &lt; 30 % * residual diameter stenosis visual estimate . 2 . Clinical Success : improvement clinical Rutherford-Becker category index procedure . 3 . Procedural Success : defined Device Success without occurrence major adverse event ( MAE ) index hospitalization . 4 . MAE rate 30 day post index procedure . 5 . Thrombotic occlusion Target Lesion 30 day , 6 month , 12 month post index procedure . 6 . Clinically driven Target Lesion Revascularization ( TLR ) 6 month , 12 month post index procedure . 7 . Binary Restenosis rate 6 month 12 month FU . Follow-Up Schedule : All patient follow pre-study , 24 hour post-study , follow-up evaluation 30 day , 6 month , 12 month Index procedure . Clinical evaluation ankle brachial index ( ABI ) assess pre-study , 24 hour post-study , 6 month , 12 month Index procedure . Colour Doppler ultrasound perform 24 hour post-study , 6 month , 12 month Index procedure . Computed tomography angiography ( CTA ) perform 6 month Index procedure . Study duration : The enrolment period follow-up study duration project 24 month . Subject duration : Each subject expect enrol study 12 month . Inclusion Criteria : All criterion 1-6 apply inclusion . 1 . Age &gt; 50 year 2 . Patient legally authorize provide write informed consent 3 . Patient willing likely comply follow schedule 4 . Patient symptomatic Rutherford-Becker 2-5 ( Fontaine II-IV ) 5 . In-stent restenosis SFA P1 segment popliteal artery ( PA ) 6 . Tibial run-off least 1 artery however may stenotic amenable PTA Exclusion Criteria : 1 . Patients unable give inform consent 2 . Patients enrol another study investigational drug device 3 . Major surgical procedure ( include minor amputation ) within 30 day prior study plan within 30 day entry study 4 . Pregnancy 5 . Patients know allergy , hypersensitivity intolerance radiologic contrast medium , ASA , Clopidogrel Ticlopidine , Paclitaxel 6 . Life expectancy &lt; 1 year Blood test : Total blood count , hematocrit , coagulation parameter , renal function parameter , fibrinogen hsCRP take Index procedure . At 6 month follow creatinine , fibrinogen hsCRP take . Interventions : Interventions perform percutaneously antegrade contralateral cross-over approach use 6 French sheath . Biplane DSA include ruler fix patient thigh perform use two view least 30Â° apart evaluate lesion morphology , inflow disease run-off . After successful wire passage target lesion , patient randomly assign either Paclitaxel elute balloon angioplasty ( PePTA ) standard percutaneous balloon angioplasty ( sPTA ) use computer generate random digit seal envelope . Medical Therapy : All patient receive aspirin 100mg daily indefinitely clopidogrel 75 mg daily 3 month post intervention . Aspirin clopidogrel initiate least 1 day prior intervention , otherwise load dose 300 mg clopidogrel give intervention . Control CTA CDUS : Angiographic evaluation restenosis 6 month perform use contrast enhance CTA . At colour Doppler ultrasound evaluation wave form , peak systolic diastolic velocity peak systolic velocity ration ( PSV ratio ) measure 24 hour , 6 12 month post Index procedure . CDUS finding consistent significant restenosis ( &gt; 50 % ) , evidence PSV ratio &gt; 2.5 within treat arterial segment occlusion treat arterial segment .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>All criterion 16 apply inclusion . 1 . Age &gt; 50 year 2 . Patient legally authorize provide write informed consent 3 . Patient willing likely comply follow schedule 4 . Patient symptomatic RutherfordBecker 25 ( Fontaine IIIV ) 5 . Instent restenosis SFA P1 segment popliteal artery ( PA ) 6 . Tibial runoff least 1 artery however may stenotic amenable PTA 1 . Patients unable give inform consent 2 . Patients enrol another study investigational drug device 3 . Major surgical procedure ( include minor amputation ) within 30 day prior study plan within 30 day entry study 4 . Pregnancy 5 . Patients know allergy , hypersensitivity intolerance radiologic contrast medium , ASA , Clopidogrel Ticlopidine , Paclitaxel 6 . Life expectancy &lt; 1 year</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>peripheral arterial disease</keyword>
	<keyword>in-stent restenosis</keyword>
	<keyword>drug elute balloon</keyword>
</DOC>